IN
Ind-Swift Laboratories Ltd (INDSWFTLAB)
₹398.20
Mkt cap
₹3,246 Cr
P/E ratio
49.90
P/B
2.50
Div yield
0.00%
ROE
3.87%
ROCE
4.70%
EPS (TTM)
₹7.98
Book value
₹159
52W range
87–425
Sector
Healthcare
Price history
Previous close
Incorporated in 1995, Ind-Swift Laboratories Ltd is a pharmaceutical company focused on finished dosage formulations (FDF). Co. manufactures tablets, capsules, ointments, injectables, liquids and dry syrups across therapies including gynaecology, paediatrics, cardiology, diabetology and dermatology. Operations span domestic formulations and international markets through own brands, contract manufacturing and out-licensing. [1]
NSE INDSWFTLABBSE 532305
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−6.25% from high₹398
₹87+356.91% from low₹425
Current
₹398.20
Prev close
₹385.00
Day
+3.43%
Price performance
1D
+3.43%
1W
−2.43%
1M
+6.84%
3M
+85.08%
6M
+186.78%
1Y
+298.48%
YTD
+334.95%
Financials
Revenue, profit & margin
P/E ratio
49.9×
INDSWFTLAB is 44% above the sector median of 34.6×
INDSWFTLAB49.9×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 | |
| Expenses | 250 | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 | |
| Operating Profit | 60 | 66 | 52 | 91 | -10 | -12 | -7 | -9 | 4 | 1 | 4 | 21 | 33 | |
| OPM % | 19% | 23% | 18% | 17% | -29% | -99% | -5% | -7% | 2.4% | 1.0% | 2.8% | 12% | 17% | |
| Other Income | 6 | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 18 | 22 | -3 | 7 | |
| Interest | 20 | 21 | 21 | 3 | 0 | 0 | 10 | -27 | 1 | 2 | 1 | -2 | 1 | |
| Depreciation | 14 | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 | |
| Profit before tax | 32 | 39 | 24 | 527 | 1 | 1 | -7 | 230 | 10 | 10 | 16 | 12 | 33 | |
| Tax % | 45% | 18% | 19% | 6% | -3% | 31% | -16% | 4% | 17% | 22% | 42% | -26% | 25% | |
| Net Profit | 17 | 32 | 19 | 494 | 1 | 0 | -5 | 222 | 9 | 8 | 10 | 15 | 25 | |
| EPS in Rs | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +20.00% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26◦ |
| Earnings day | +20.00% |
| +1 day | +26.45% |
| +5 days | +46.21% |
| +15 days | +55.18% |
| +30 days | +70.73% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202642.93%Promoter
Promoters42.93%0.07
FIIs10.70%3.18
DIIs0.17%0.17
Public46.19%3.05
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Ind-Swift Labs. | ₹373.25 | 49.87 | 3,246 | 0.00% | 25 | +183.47% | 191 | +25.35% | 4.70% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts7
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment 17 Sep - Allotted 70 lakh convertible warrants to promoter group at Rs 196 each, raising Rs 34.3 crore.Announcement under Regulation 30 (LODR)-Newspaper Publication 6 SepReg. 34 (1) Annual Report. 5 SepNotice Of 31St Annual General Meeting Scheduled To Be Held On Sept. 30, 2026 5 SepAnnouncement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Please refer attached newspaper publication dated 04.09.2026.